Reshape Lifesciences (RSLS) Hits New 1-Year Low at $1.41
Reshape Lifesciences Inc (NASDAQ:RSLS) shares reached a new 52-week low during trading on Thursday . The company traded as low as $1.41 and last traded at $1.53, with a volume of 8571 shares. The stock had previously closed at $1.83.
A number of research firms have commented on RSLS. ValuEngine downgraded Reshape Lifesciences from a “buy” rating to a “hold” rating in a report on Tuesday, October 2nd. Zacks Investment Research raised Reshape Lifesciences from a “sell” rating to a “hold” rating in a report on Thursday, July 26th. Finally, LADENBURG THALM/SH SH downgraded Reshape Lifesciences from a “buy” rating to a “neutral” rating in a report on Friday, August 3rd.
Reshape Lifesciences (NASDAQ:RSLS) last released its earnings results on Tuesday, August 14th. The medical device company reported ($672.00) EPS for the quarter, missing analysts’ consensus estimates of ($250.60) by ($421.40). Reshape Lifesciences had a negative return on equity of 70.96% and a negative net margin of 2,397.35%. The firm had revenue of $0.65 million for the quarter. Analysts anticipate that Reshape Lifesciences Inc will post -371.83 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Reshape Lifesciences (RSLS) Hits New 1-Year Low at $1.41” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/15/reshape-lifesciences-rsls-hits-new-1-year-low-at-1-41.html.
Reshape Lifesciences Company Profile (NASDAQ:RSLS)
ReShape Lifesciences Inc, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses.
See Also: What are the most popular ETFs
Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.